Novo Nordisk A/S (NYSE:NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease.

The two trials were randomised, double-blinded, enrolled 3,808 adults, and evaluated the efficacy and safety of oral semaglutide compared to placebo on top of standard of care.

The decision to pursue an Alzheimer’s disease indication with semaglutide was based on real-world evidence studies, preclinical models, as well as post-hoc analyses from diabetes and obesity trials.

Also Read: FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer’s Therapy

The evoke and evoke+ trials did not confirm superiority of semaglutide ...